Results 191 to 200 of about 1,255,934 (217)

Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model

Thrombosis Research, 2021
Crescence Lydie, Roxane Darbousset, Laurence Panicot-Dubois   +2 more
exaly  

P2Y12 Receptor Modulates Sepsis-Induced Inflammation

Arteriosclerosis, Thrombosis, and Vascular Biology, 2016
Elisabetta Liverani, Satya P Kunapuli, Laurie Kilpatrick   +2 more
exaly  

Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist

Cardiovascular Therapeutics, 2009
Steen Husted, J J J van Giezen, J J J van Giezen   +2 more
exaly  

Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects

Xenobiotica, 2020
Jan Jaap van Lier, Jasper Dingemanse, Mike Ufer   +2 more
exaly  

P2Y12-Receptor Antagonists and the Concept of Tailored Strategy

2016
Boukhris M, Tomasello SD, Ibn Elhadj ZI, GALASSI, ALFREDO   +3 more
openaire   +2 more sources

Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus

Circulation, 2017
Liang Hu, Yan Yan, Hongmei YAN
exaly  

Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties

Drugs, 2013
Stefano Bellosta, Nicola Ferri, Alberto Corsini   +2 more
exaly  

Extracellular ADP augments microglial inflammasome and NF-κB activation via the P2Y12 receptor

European Journal of Immunology, 2020
Hiroshi Sakuma, Minoru Saitoe, Tomohiro Morio   +2 more
exaly  

The role of P2Y12 receptor antagonists in thrombogenesis

2017
openaire   +1 more source

International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies

Circulation, 2017
Dominick Angiolillo, Francesco Franchi
exaly